Author: Gudisa Bereda

Abstract:

Benign prostatic hyperplasia can be arising in the periurethral and transition zones of the prostatic gland and represents an inescapable phenomenon for the ageing male population. Benign prostatic hyperplasia can be described as a common and age-related disease as it is estimated that about 50% of men over the age of 50, and 80% of those older than 70 suffer from it. The risk factors for benign prostatic hyperplasia involve metabolic syndrome, diabetes, obesity, hypertension, diet and sex hormone levels. The histopathology of benign prostatic hyperplasia characteristically involves of a dual hyperplasia of the epithelial and stromal compartment of the transitional zone of the prostate. The medical managements broadly used today for treatment of benign prostatic hyperplasia are targeted to diminishing bladder outlet obstruction in order to decrease prostate volume and relax prostate smooth muscle tension. Alpha-1-blockers are considered as the first-line treatment and are used in the presence of moderate-to-severe symptomatology. Terazosin and doxazosin are non-specific alpha-1 receptor blockers confirmed for hypertension, as well as benign prostatic hyperplasia.